Amgen (NASDAQ:AMGN) today announced detailed results from the Phase 3 VESALIUS-CV clinical trial, which showed that Repatha® (evolocumab) achieved statistically significant and clinically meaningful ...
THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha ® (evolocumab) to ...
By Deena Beasley (Reuters) -Adding Amgen's cholesterol drug Repatha to standard therapy reduced major cardiovascular events ...
Repatha (evolocumab) is an injectable medicine that helps lower levels of low-density lipoprotein cholesterol (LDL), often called “bad” cholesterol. Approved in 2015, Repatha can now be used in adults ...
Intervention/Treatment: The study tests the intervention of Repatha®, a medication used alongside standard care, to assess its impact on reducing cardiovascular risks such as death, myocardial ...
Amgen to present new data from cardiovascular portfolio, including late-breaking results from phase 3 VESALIUS-CV trial of Repatha at AHA scientific sessions: Thousand Oaks, Calif ...
Amgen, a biotechnology company that discovers, develops, manufactures and delivers innovative medicines, announced that the US Food and Drug Administration (FDA) has broadened the approved use of ...
In March 2015, Amgen is preparing for the launch of Repatha, a new molecule that has demonstrated a remarkable ability to treat high cholesterol. Through a series of clinical trials, Amgen has proven ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback